Opinion | The Rich Get Fit, And Poor Get 'Lectures' - That's India's Ozempic Problem

The rise of a grey market in India, where unsupervised doses are sold at exorbitant rates, demonstrates that excessive ...

Novo Cuts Outlook Again, Highlighting Obesity Struggles

Novo Nordisk A/S trimmed its forecast for a fourth time this year on lagging sales of its blockbuster drugs Wegovy and ...